# Trince

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trince

- Industry: Biotechnology
- Headquarters: Gent, Belgium
- Website: www.trince.be
- Total disclosed funding: $2.3M
- Latest round: Series A (Dec 7, 2021)
- Investors on record: 2

## About

Founded in 2021 by Philip Mathuis, and Kevin Braeckmans, and based in Asse, Belgium, Trince a spin-off company from Ghent University operates as a biotechnology company that develops cancer solutions. In December 2025, Trince PLC raised EUR 5.2 million in venture funding.

The company's LumiPore transfection platform combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane.

The company plans to use December 2025 the venture funding to accelerate commercialization, advance technology developments in screening and drug discovery, and support long-term growth initiatives.

## Funding rounds

- Series A, Dec 7, 2021, $2.3M — Qbic Fund, Novalis Biotech

## Investors

- Qbic Fund (https://capitalatlas.ai/funds/qbic-fund) — Series A
- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Series A